Lv71
3965 积分 2022-01-07 加入
企业绿色发展信息披露与盈余管理:“言以昭信”还是“言多伤
1个月前
已完结
企业绿色发展信息披露与盈余管理:“言以昭信”还是“言多伤幸”?
1个月前
已完结
Predictors of treatment-emergent resistance to dolutegravir
2个月前
已完结
甘草素联合阿霉素诱导人肝癌HepG2细胞及裸鼠肝癌移植瘤凋亡及其分子机制的研究
4个月前
已完结
2019年江苏省学校食物中毒暴发事件分析
4个月前
已完结
2016年江苏省食源性疾病暴发事件流行病学分析
4个月前
已完结
Safety and efficacy of switching to bictegravir–lenacapavir versus continuing bictegravir–emtricitabine–tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
5个月前
已完结
Safety and efficacy of switching to bictegravir–lenacapavir versus continuing bictegravir–emtricitabine–tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
5个月前
已关闭
Safety and efficacy of switching to bictegravir–lenacapavir versus continuing bictegravir–emtricitabine–tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
5个月前
已关闭
Safety and efficacy of switching to bictegravir–lenacapavir versus continuing bictegravir–emtricitabine–tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
5个月前
已关闭